Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Human Psychopharmacology|March 28, 2013
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophreniaMichael F Egan, Xin Zhao, Andrew Smith, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 15, 2013
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parametersPieter-Jan de Kam, Rachid El Galta, Annelieke C Kruithof, et al.
Neuron|August 15, 2001
The expression of vesicular glutamate transporters defines two classes of excitatory synapseR T Fremeau, M D Troyer, I Pahner, et al.
Drug Design, Development and Therapy|September 15, 2018
Asenapine pharmacokinetics and tolerability in a pediatric populationPeter Dogterom, Robert Riesenberg, Rik de Greef, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 8, 2014
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjectsPieter-Jan De Kam, Annelieke C Kruithof, Marie-José van Lierop, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 17, 2006
Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosisKristin E Larsen, Yvonne Schmitz, Matthew D Troyer, et al.
Brain Research|November 4, 1996
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disordersD A Loeffler, P A LeWitt, P L Juneau, et al.
Clinical Pharmacology and Therapeutics|October 23, 2018
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled StudyK Chris Min, Marissa F Dockendorf, John Palcza, et al.
The AAPS Journal|August 28, 2014
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II designJoanna Z Peng, William S Denney, Bret J Musser, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 8, 2006
Alpha-synuclein overexpression increases cytosolic catecholamine concentrationEugene V Mosharov, Roland G W Staal, Jordi Bové, et al.
Pageof 9